Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review

Irbaz Bin Riaz, Muhammad Umar, Umar Zahid, Muhammad Husnain, Ahmad Iftikhar, Ali McBride, Jawad Bilal, Asad Javed, Sara Akbar, Parminder Singh, Zeeshan Ali, Qurat Ul Ain Riaz Sipra, Farva Razia Gondal, Frederick Ahman, Faiz Anwer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Approximately 20–30% of patients with metastatic germ cell cancers (GCCs) can develop relapsed or refractory (RR) disease, about 40–50% of patients who relapse after salvage chemotherapy may reach long-term remission. The goal of this review was to identify patients who appear to benefit from high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). To access this, we performed a systematic medical literature review to evaluate the effectiveness of HDCT in the frontline setting, as well as in patients with RR testicular cancer. We searched databases for interventional clinical studies and identified 5883 studies. We selected 49 studies for inclusion, which included a total of 5985 patients. Seventeen studies reported results of newly diagnosed poor-risk GCC patients and 32 studies reported results of RR patients. For newly diagnosed patients with poor prognostic predictors, a risk adjusted strategy using unfavorable tumor marker decline with initial standard chemotherapy regimen and upfront HDCT demonstrated improved outcomes. Our data suggest a minimum of two HDCT cycles with ASCT should be standard of care for patients with RR GCC. Failure of HDCT results in a poor prognosis with only 10% of patients achieving lasting remission with salvage therapy.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalBone Marrow Transplantation
DOIs
StateAccepted/In press - Apr 27 2018

Fingerprint

Autologous Transplantation
Testicular Neoplasms
Drug Therapy
Germ Cell and Embryonal Neoplasms
Therapeutics
Stem Cells
Transplants
Salvage Therapy
Standard of Care
Tumor Biomarkers
Databases
Recurrence

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer : a systematic review. / Bin Riaz, Irbaz; Umar, Muhammad; Zahid, Umar; Husnain, Muhammad; Iftikhar, Ahmad; McBride, Ali; Bilal, Jawad; Javed, Asad; Akbar, Sara; Singh, Parminder; Ali, Zeeshan; Sipra, Qurat Ul Ain Riaz; Gondal, Farva Razia; Ahman, Frederick; Anwer, Faiz.

In: Bone Marrow Transplantation, 27.04.2018, p. 1-13.

Research output: Contribution to journalArticle

Bin Riaz, I, Umar, M, Zahid, U, Husnain, M, Iftikhar, A, McBride, A, Bilal, J, Javed, A, Akbar, S, Singh, P, Ali, Z, Sipra, QUAR, Gondal, FR, Ahman, F & Anwer, F 2018, 'Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review', Bone Marrow Transplantation, pp. 1-13. https://doi.org/10.1038/s41409-018-0188-3
Bin Riaz, Irbaz ; Umar, Muhammad ; Zahid, Umar ; Husnain, Muhammad ; Iftikhar, Ahmad ; McBride, Ali ; Bilal, Jawad ; Javed, Asad ; Akbar, Sara ; Singh, Parminder ; Ali, Zeeshan ; Sipra, Qurat Ul Ain Riaz ; Gondal, Farva Razia ; Ahman, Frederick ; Anwer, Faiz. / Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer : a systematic review. In: Bone Marrow Transplantation. 2018 ; pp. 1-13.
@article{3d11df8e56804841b656a1eaa7bc80ca,
title = "Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review",
abstract = "Approximately 20–30{\%} of patients with metastatic germ cell cancers (GCCs) can develop relapsed or refractory (RR) disease, about 40–50{\%} of patients who relapse after salvage chemotherapy may reach long-term remission. The goal of this review was to identify patients who appear to benefit from high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). To access this, we performed a systematic medical literature review to evaluate the effectiveness of HDCT in the frontline setting, as well as in patients with RR testicular cancer. We searched databases for interventional clinical studies and identified 5883 studies. We selected 49 studies for inclusion, which included a total of 5985 patients. Seventeen studies reported results of newly diagnosed poor-risk GCC patients and 32 studies reported results of RR patients. For newly diagnosed patients with poor prognostic predictors, a risk adjusted strategy using unfavorable tumor marker decline with initial standard chemotherapy regimen and upfront HDCT demonstrated improved outcomes. Our data suggest a minimum of two HDCT cycles with ASCT should be standard of care for patients with RR GCC. Failure of HDCT results in a poor prognosis with only 10{\%} of patients achieving lasting remission with salvage therapy.",
author = "{Bin Riaz}, Irbaz and Muhammad Umar and Umar Zahid and Muhammad Husnain and Ahmad Iftikhar and Ali McBride and Jawad Bilal and Asad Javed and Sara Akbar and Parminder Singh and Zeeshan Ali and Sipra, {Qurat Ul Ain Riaz} and Gondal, {Farva Razia} and Frederick Ahman and Faiz Anwer",
year = "2018",
month = "4",
day = "27",
doi = "10.1038/s41409-018-0188-3",
language = "English (US)",
pages = "1--13",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer

T2 - a systematic review

AU - Bin Riaz, Irbaz

AU - Umar, Muhammad

AU - Zahid, Umar

AU - Husnain, Muhammad

AU - Iftikhar, Ahmad

AU - McBride, Ali

AU - Bilal, Jawad

AU - Javed, Asad

AU - Akbar, Sara

AU - Singh, Parminder

AU - Ali, Zeeshan

AU - Sipra, Qurat Ul Ain Riaz

AU - Gondal, Farva Razia

AU - Ahman, Frederick

AU - Anwer, Faiz

PY - 2018/4/27

Y1 - 2018/4/27

N2 - Approximately 20–30% of patients with metastatic germ cell cancers (GCCs) can develop relapsed or refractory (RR) disease, about 40–50% of patients who relapse after salvage chemotherapy may reach long-term remission. The goal of this review was to identify patients who appear to benefit from high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). To access this, we performed a systematic medical literature review to evaluate the effectiveness of HDCT in the frontline setting, as well as in patients with RR testicular cancer. We searched databases for interventional clinical studies and identified 5883 studies. We selected 49 studies for inclusion, which included a total of 5985 patients. Seventeen studies reported results of newly diagnosed poor-risk GCC patients and 32 studies reported results of RR patients. For newly diagnosed patients with poor prognostic predictors, a risk adjusted strategy using unfavorable tumor marker decline with initial standard chemotherapy regimen and upfront HDCT demonstrated improved outcomes. Our data suggest a minimum of two HDCT cycles with ASCT should be standard of care for patients with RR GCC. Failure of HDCT results in a poor prognosis with only 10% of patients achieving lasting remission with salvage therapy.

AB - Approximately 20–30% of patients with metastatic germ cell cancers (GCCs) can develop relapsed or refractory (RR) disease, about 40–50% of patients who relapse after salvage chemotherapy may reach long-term remission. The goal of this review was to identify patients who appear to benefit from high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). To access this, we performed a systematic medical literature review to evaluate the effectiveness of HDCT in the frontline setting, as well as in patients with RR testicular cancer. We searched databases for interventional clinical studies and identified 5883 studies. We selected 49 studies for inclusion, which included a total of 5985 patients. Seventeen studies reported results of newly diagnosed poor-risk GCC patients and 32 studies reported results of RR patients. For newly diagnosed patients with poor prognostic predictors, a risk adjusted strategy using unfavorable tumor marker decline with initial standard chemotherapy regimen and upfront HDCT demonstrated improved outcomes. Our data suggest a minimum of two HDCT cycles with ASCT should be standard of care for patients with RR GCC. Failure of HDCT results in a poor prognosis with only 10% of patients achieving lasting remission with salvage therapy.

UR - http://www.scopus.com/inward/record.url?scp=85046042530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046042530&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0188-3

DO - 10.1038/s41409-018-0188-3

M3 - Article

C2 - 29703969

AN - SCOPUS:85046042530

SP - 1

EP - 13

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -